Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services, Rehabilitation Therapy Services, and All Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of December 31, 2017, it provided inpatient services through a network of 470 skilled nursing and assisted/senior living facilities, including 444 skilled nursing facilities and 26 stand-alone assisted/senior living facilities across 30 states. Genesis HealthCare, Inc. also supplied rehabilitation and respiratory therapy to approximately 1,600 healthcare locations in 46 states and the District of Columbia. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Skilled nursing care facilities
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:GEN
Previous SymbolNYSE:SKH
CUSIPN/A
Phone610-444-6350
Debt
Debt-to-Equity RatioN/A
Current Ratio0.97
Quick Ratio0.97
Price-To-Earnings
Trailing P/E Ratio-0.66
Forward P/E Ratio-1.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.37 billion
Price / Sales0.04
Cash Flow$2.3333 per share
Price / Cash Flow0.60
Book Value($10.54) per share
Price / Book-0.13
Profitability
EPS (Most Recent Fiscal Year)($2.11)
Net Income$-578,980,000.00
Net Margins-4.99%
Return on EquityN/A
Return on Assets-2.66%
Miscellaneous
Employees68,700
Outstanding Shares161,680,000
Market Cap$252.22 million
OptionableOptionable
Genesis Healthcare (NYSE:GEN) Frequently Asked Questions
What is Genesis Healthcare's stock symbol?
Genesis Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "GEN."
How were Genesis Healthcare's earnings last quarter?
Genesis Healthcare Inc (NYSE:GEN) issued its earnings results on Wednesday, November, 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.25. The business earned $1.22 billion during the quarter, compared to analysts' expectations of $1.21 billion. During the same quarter in the previous year, the firm posted ($0.34) EPS. View Genesis Healthcare's Earnings History.
When is Genesis Healthcare's next earnings date?
What price target have analysts set for GEN?
4 analysts have issued 12 month price objectives for Genesis Healthcare's stock. Their predictions range from $1.75 to $7.00. On average, they expect Genesis Healthcare's share price to reach $3.3125 in the next year. This suggests a possible upside of 136.6% from the stock's current price. View Analyst Price Targets for Genesis Healthcare.
What is the consensus analysts' recommendation for Genesis Healthcare?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genesis Healthcare in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genesis Healthcare.
Has Genesis Healthcare been receiving favorable news coverage?
News coverage about GEN stock has trended somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genesis Healthcare earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.
Who are some of Genesis Healthcare's key competitors?
Some companies that are related to Genesis Healthcare include Audentes Therapeutics (BOLD), Deciphera Pharmaceuticals (DCPH), Retrophin (RTRX), Cardiovascular Systems (CSII), Rhythm Pharmaceuticals (RYTM), Addus Homecare (ADUS), Natera (NTRA), Amphastar Pharmaceuticals (AMPH), Intersect ENT (XENT), Tactile Systems Technology (TCMD), Novavax (NVAX), TherapeuticsMD (TXMD), Homology Medicines (FIXX), BioCryst Pharmaceuticals (BCRX) and InVitae (NVTA).
Who are Genesis Healthcare's key executives?
Genesis Healthcare's management team includes the folowing people:
- Mr. George V. Hager Jr., CEO & Director (Age 62)
- Mr. Thomas DiVittorio, CFO, Sr. VP, Treasurer & Assistant Sec. (Age 50)
- Mr. Paul David Bach, COO & Exec. VP (Age 59)
- Dr. JoAnne Susan Reifsnyder Ph.D., MSN, MBA, FAAN, Exec. VP of Clinical Operations & Chief Nursing Officer (Age 59)
- Mr. Richard L. Castor, Chief Information Officer & Sr. VP (Age 63)
Who are Genesis Healthcare's major shareholders?
Genesis Healthcare's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include V3 Capital Management L.P. (2.21%), First Washington CORP (2.11%), BlackRock Inc. (2.00%), Columbia Pacific Advisors LLC (1.98%), Renaissance Technologies LLC (1.79%) and Vanguard Group Inc (1.50%). Company insiders that own Genesis Healthcare stock include Daniel Allen Hirschfeld, David A Reis, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young and Thomas Divittorio. View Institutional Ownership Trends for Genesis Healthcare.
Which major investors are selling Genesis Healthcare stock?
GEN stock was sold by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., JPMorgan Chase & Co. and Macquarie Group Ltd.. Company insiders that have sold Genesis Healthcare company stock in the last year include David A Reis, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young and Thomas Divittorio. View Insider Buying and Selling for Genesis Healthcare.
Which major investors are buying Genesis Healthcare stock?
GEN stock was acquired by a variety of institutional investors in the last quarter, including V3 Capital Management L.P., Acadian Asset Management LLC, Renaissance Technologies LLC, First Washington CORP, Columbia Pacific Advisors LLC, Bridgeway Capital Management Inc., Connor Clark & Lunn Investment Management Ltd. and BlackRock Inc.. View Insider Buying and Selling for Genesis Healthcare.
How do I buy shares of Genesis Healthcare?
Shares of GEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genesis Healthcare's stock price today?
One share of GEN stock can currently be purchased for approximately $1.40.
How big of a company is Genesis Healthcare?
Genesis Healthcare has a market capitalization of $252.22 million and generates $5.37 billion in revenue each year. The company earns $-578,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Genesis Healthcare employs 68,700 workers across the globe.
What is Genesis Healthcare's official website?
How can I contact Genesis Healthcare?
Genesis Healthcare's mailing address is 101 EAST STATE STREET, KENNETT SQUARE PA, 19348. The company can be reached via phone at 610-444-6350 or via email at [email protected]
MarketBeat Community Rating for Genesis Healthcare (NYSE GEN)
MarketBeat's community ratings are surveys of what our community members think about Genesis Healthcare and other stocks. Vote "Outperform" if you believe GEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
